Cwm LLC Decreases Holdings in Hologic, Inc. (NASDAQ:HOLX)

Cwm LLC decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 4.9% during the 3rd quarter, Holdings Channel.com reports. The fund owned 9,162 shares of the medical equipment provider’s stock after selling 476 shares during the period. Cwm LLC’s holdings in Hologic were worth $746,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Innealta Capital LLC purchased a new stake in shares of Hologic during the 2nd quarter worth approximately $25,000. iA Global Asset Management Inc. purchased a new stake in shares of Hologic during the 1st quarter worth approximately $37,000. Sunbelt Securities Inc. purchased a new stake in shares of Hologic during the 2nd quarter worth approximately $37,000. Cranbrook Wealth Management LLC purchased a new stake in shares of Hologic during the 2nd quarter worth approximately $47,000. Finally, Mather Group LLC. purchased a new stake in shares of Hologic during the 1st quarter worth approximately $48,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Trading Up 1.4 %

HOLX stock opened at $81.57 on Friday. The company has a market cap of $19.04 billion, a price-to-earnings ratio of 41.62, a PEG ratio of 2.89 and a beta of 0.98. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The business has a fifty day simple moving average of $80.94 and a 200-day simple moving average of $77.73. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.93 EPS. On average, equities research analysts expect that Hologic, Inc. will post 4.09 EPS for the current year.

Insider Transactions at Hologic

In other news, insider Benjamin Jordan Cohn sold 5,093 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total transaction of $417,575.07. Following the completion of the sale, the insider now directly owns 10,476 shares in the company, valued at $858,927.24. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the sale, the insider now directly owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Benjamin Jordan Cohn sold 5,093 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total transaction of $417,575.07. Following the sale, the insider now directly owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.75% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on HOLX. Citigroup lowered Hologic from a “buy” rating to a “neutral” rating and reduced their target price for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. StockNews.com lowered Hologic from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 27th. Evercore ISI upped their target price on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research note on Tuesday, October 1st. Leerink Partners reduced their target price on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 target price on shares of Hologic in a research note on Tuesday. Five research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Hologic has a consensus rating of “Moderate Buy” and an average price target of $87.50.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.